The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.
Official Title: A Randomized, Open Label, Two Arm, Single Dose, Crossover, Bioequivalence Study of Ayana Pharma's Doxorubicin Hydrochloride Liposome Injection (LC-101) (Investigational Product) and the US Reference Standard Doxorubicin Hydrochloride Liposome Injection (Sun Pharma), in Subjects With Ovarian Cancer.
Study ID: NCT03681548
Brief Summary: Bioequivalence study is proposed to be carried out on patients of ovarian cancer, who are already receiving or who in the opinion of their treating physicians are candidates for Doxorubicin liposomal injection therapy .
Detailed Description: This study is a randomized, open label, two arm, single dose, crossover bioequivalence study. This study will be conducted in female subjects aged 18 to 65 years diagnosed with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy and who are already receiving or scheduled to start therapy with Doxorubicin Hydrochloride Liposome Injection product. Each subject will be randomized to one of the two treatment sequences (RT or TR) according to a randomization scheme prepared prior to start of the trial. Serial blood samples for determination of free and liposomal encapsulated doxorubicin plasma concentration for PK analysis will be obtained in each cycle., This study has an adaptive 2-stage design. A sufficient number of subjects with ovarian cancer shall be recruited to have approximately 42 evaluable subjects completing all follow up procedures (Stage 1). An interim analysis of free and encapsulated doxorubicin will be performed at the end of Stage 1. If the bioequivalence of encapsulated and free doxorubicin has been established, then the study will be stopped. Otherwise, the study may continue into Stage 2 with additional number of ovarian cancer subjects. A final evaluation of bioequivalence based on free and encapsulated doxorubicin will be performed at the end of Stage 2 and will include all enrolled subjects completing the study. Bioequivalence criteria: the 94.12% confidence interval of the ratio of geometric means of TEST to REFERENCE for Cmax, AUC0-t, AUC0-∞, for free and encapsulated doxorubicin should be between 80.00% and 125.00%.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
MNJ Institute of Oncology & Regional Cancer Center, Hyderabad, Andhra Pradesh, India
HCG City Cancer Centre, Vijayawada, Andhra Pradesh, India
Mahatma Gandhi Cancer Hospital & Research Institute, Visakhapatnam, Andhra Pradesh, India
Nirmal Hospital Pvt. Ltd., Surat, Gujarat, India
Unique Hospital - Multispeciality and Research Institute, Sūrat, Gujarat, India
Aman Hospital and Research Center, Vadodara, Gujarat, India
Kailash Cancer Hospital And Research Center, Vadodara, Gujarat, India
K R Hospital, Mysore, Karnataka, India
Apex Wellness Rishikesh Hospital, Nashik, Maharashtra, India
HCG Manavata Cancer Centre, Nashik, Maharashtra, India
Noble Hospital Pvt Ltd., Pune, Maharashtra, India
Sparsh Hospitals & Critical Care (P) Ltd., Bhubaneshwar, Odisha, India
Sri Ramachandra Medical Centre, Chennai, Tamil Nadu, India
Saveetha Medical College & Hospital, Chennai, Tamil Nadu, India
VGM Hospital, Coimbatore, Tamil Nadu, India
Name: Rakesh J Patel, MD Pharm
Affiliation: Lambda Therapeutic Research Ltd.
Role: STUDY_DIRECTOR